Inhibition by arsenic trioxide of human hepatoma cell growth

Makoto Oketani, Kazunori Kohara, Demidmaa Tuvdendorj, Kenji Ishitsuka, Yasuji Komorizono, Kazuaki Ishibashi, Terukatsu Arima

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Arsenic trioxide (As2O3) has been shown to be effective for treatment of patients with refractory or relapsed acute promyelocytic leukemia and a variety of other malignant hematopoetic disorders. We studied the effect of this agent on proliferation of human hepatoma-derived cell lines (SK-Hep-1, HepG2, and HuH7). In HuH7 cells, As2O3 reduced proliferation time- and dose-dependently at 1 and 2 μM, while in SK-Hep-1 and HepG2 cells, As2O3 inhibited proliferation at 2 and 4 μM respectively. Cell cycle analysis by flow cytometry showed that As2O3 induced apoptosis in these hepatoma-derived cells as confirmed by appearance of sub-G1 cells. Sensitivity of hepatoma-derived cells to As2O3 was inversely related to their intracellular glutathione (GSH) and intensity of GSH synthesis. Arsenic sensitivity was restored to relatively resistant cell lines when GSH was depleted by L-buthionine sulfoximine (BSO). These results indicate that As2O3 may have therapeutic potential for treatment of hepatocellular carcinoma.

Original languageEnglish (US)
Pages (from-to)147-153
Number of pages7
JournalCancer Letters
Volume183
Issue number2
DOIs
StatePublished - Sep 26 2002
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Growth
Buthionine Sulfoximine
Cell Line
Acute Promyelocytic Leukemia
Hep G2 Cells
Arsenic
arsenic trioxide
Glutathione
Cell Cycle
Flow Cytometry
Therapeutics
Apoptosis

Keywords

  • Apoptosis
  • Arsenic trioxide
  • Buthionine sulfoximine
  • Glutathione
  • Hepatoma

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Oketani, M., Kohara, K., Tuvdendorj, D., Ishitsuka, K., Komorizono, Y., Ishibashi, K., & Arima, T. (2002). Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Letters, 183(2), 147-153. https://doi.org/10.1016/S0304-3835(01)00800-X

Inhibition by arsenic trioxide of human hepatoma cell growth. / Oketani, Makoto; Kohara, Kazunori; Tuvdendorj, Demidmaa; Ishitsuka, Kenji; Komorizono, Yasuji; Ishibashi, Kazuaki; Arima, Terukatsu.

In: Cancer Letters, Vol. 183, No. 2, 26.09.2002, p. 147-153.

Research output: Contribution to journalArticle

Oketani, M, Kohara, K, Tuvdendorj, D, Ishitsuka, K, Komorizono, Y, Ishibashi, K & Arima, T 2002, 'Inhibition by arsenic trioxide of human hepatoma cell growth', Cancer Letters, vol. 183, no. 2, pp. 147-153. https://doi.org/10.1016/S0304-3835(01)00800-X
Oketani M, Kohara K, Tuvdendorj D, Ishitsuka K, Komorizono Y, Ishibashi K et al. Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Letters. 2002 Sep 26;183(2):147-153. https://doi.org/10.1016/S0304-3835(01)00800-X
Oketani, Makoto ; Kohara, Kazunori ; Tuvdendorj, Demidmaa ; Ishitsuka, Kenji ; Komorizono, Yasuji ; Ishibashi, Kazuaki ; Arima, Terukatsu. / Inhibition by arsenic trioxide of human hepatoma cell growth. In: Cancer Letters. 2002 ; Vol. 183, No. 2. pp. 147-153.
@article{9516b123211a4d3e889dcb0944910be8,
title = "Inhibition by arsenic trioxide of human hepatoma cell growth",
abstract = "Arsenic trioxide (As2O3) has been shown to be effective for treatment of patients with refractory or relapsed acute promyelocytic leukemia and a variety of other malignant hematopoetic disorders. We studied the effect of this agent on proliferation of human hepatoma-derived cell lines (SK-Hep-1, HepG2, and HuH7). In HuH7 cells, As2O3 reduced proliferation time- and dose-dependently at 1 and 2 μM, while in SK-Hep-1 and HepG2 cells, As2O3 inhibited proliferation at 2 and 4 μM respectively. Cell cycle analysis by flow cytometry showed that As2O3 induced apoptosis in these hepatoma-derived cells as confirmed by appearance of sub-G1 cells. Sensitivity of hepatoma-derived cells to As2O3 was inversely related to their intracellular glutathione (GSH) and intensity of GSH synthesis. Arsenic sensitivity was restored to relatively resistant cell lines when GSH was depleted by L-buthionine sulfoximine (BSO). These results indicate that As2O3 may have therapeutic potential for treatment of hepatocellular carcinoma.",
keywords = "Apoptosis, Arsenic trioxide, Buthionine sulfoximine, Glutathione, Hepatoma",
author = "Makoto Oketani and Kazunori Kohara and Demidmaa Tuvdendorj and Kenji Ishitsuka and Yasuji Komorizono and Kazuaki Ishibashi and Terukatsu Arima",
year = "2002",
month = "9",
day = "26",
doi = "10.1016/S0304-3835(01)00800-X",
language = "English (US)",
volume = "183",
pages = "147--153",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Inhibition by arsenic trioxide of human hepatoma cell growth

AU - Oketani, Makoto

AU - Kohara, Kazunori

AU - Tuvdendorj, Demidmaa

AU - Ishitsuka, Kenji

AU - Komorizono, Yasuji

AU - Ishibashi, Kazuaki

AU - Arima, Terukatsu

PY - 2002/9/26

Y1 - 2002/9/26

N2 - Arsenic trioxide (As2O3) has been shown to be effective for treatment of patients with refractory or relapsed acute promyelocytic leukemia and a variety of other malignant hematopoetic disorders. We studied the effect of this agent on proliferation of human hepatoma-derived cell lines (SK-Hep-1, HepG2, and HuH7). In HuH7 cells, As2O3 reduced proliferation time- and dose-dependently at 1 and 2 μM, while in SK-Hep-1 and HepG2 cells, As2O3 inhibited proliferation at 2 and 4 μM respectively. Cell cycle analysis by flow cytometry showed that As2O3 induced apoptosis in these hepatoma-derived cells as confirmed by appearance of sub-G1 cells. Sensitivity of hepatoma-derived cells to As2O3 was inversely related to their intracellular glutathione (GSH) and intensity of GSH synthesis. Arsenic sensitivity was restored to relatively resistant cell lines when GSH was depleted by L-buthionine sulfoximine (BSO). These results indicate that As2O3 may have therapeutic potential for treatment of hepatocellular carcinoma.

AB - Arsenic trioxide (As2O3) has been shown to be effective for treatment of patients with refractory or relapsed acute promyelocytic leukemia and a variety of other malignant hematopoetic disorders. We studied the effect of this agent on proliferation of human hepatoma-derived cell lines (SK-Hep-1, HepG2, and HuH7). In HuH7 cells, As2O3 reduced proliferation time- and dose-dependently at 1 and 2 μM, while in SK-Hep-1 and HepG2 cells, As2O3 inhibited proliferation at 2 and 4 μM respectively. Cell cycle analysis by flow cytometry showed that As2O3 induced apoptosis in these hepatoma-derived cells as confirmed by appearance of sub-G1 cells. Sensitivity of hepatoma-derived cells to As2O3 was inversely related to their intracellular glutathione (GSH) and intensity of GSH synthesis. Arsenic sensitivity was restored to relatively resistant cell lines when GSH was depleted by L-buthionine sulfoximine (BSO). These results indicate that As2O3 may have therapeutic potential for treatment of hepatocellular carcinoma.

KW - Apoptosis

KW - Arsenic trioxide

KW - Buthionine sulfoximine

KW - Glutathione

KW - Hepatoma

UR - http://www.scopus.com/inward/record.url?scp=0037179548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037179548&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(01)00800-X

DO - 10.1016/S0304-3835(01)00800-X

M3 - Article

C2 - 12065089

AN - SCOPUS:0037179548

VL - 183

SP - 147

EP - 153

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -